Research programme: antituberculars - AstraZeneca

Drug Profile

Research programme: antituberculars - AstraZeneca

Alternative Names: Tuberculosis therapies - AstraZeneca/Global Alliance for TB Drug Development

Latest Information Update: 05 May 2010

Price : $50

At a glance

  • Originator AstraZeneca
  • Class
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Tuberculosis

Most Recent Events

  • 03 May 2010 AstraZeneca and The Global Alliance for TB Drug Development agree to co-develop drugs for Tuberculosis
  • 15 Sep 2009 Antimicrobial data from preclinical studies in tuberculosis presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 28 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top